Journal of cancer research and therapeutics最新文献

{"title":"Long-term outcomes of endoscopic submucosal dissection for T1b colorectal cancer.","authors":"Zhixin Cao, Jingfang Zhao, Juan Liu, Xiangguo Tian, Yongjun Shi, Junyong Zhang, Jinhua Hu, Fuli Liu","doi":"10.4103/jcrt.jcrt_515_24","DOIUrl":"10.4103/jcrt.jcrt_515_24","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic submucosal dissection (ESD) is a standardized procedure for intramucosal and slightly invasive submucosal colorectal cancers (CRC). However, the role of ESD for T1b (depth of submucosal invasion: ≥1,000 μm) CRC remains unclear. This study aimed to investigate the long-term efficacy and safety of ESD for T1b CRC.</p><p><strong>Methods: </strong>This study involved 50 patients with T1b CRC who underwent ESD, including 31 who received subsequent surgery (ESD + surgery group) and 19 who reported comorbidities or refused subsequent surgery (ESD-alone group). The clinical outcomes, lymph node metastasis (LNM) rate, and recurrence and survival rates were determined.</p><p><strong>Results: </strong>All the patients achieved en-bloc resection, and 41 patients achieved R0 resection. The mean tumor diameter was 31.2 ± 11.9 mm. LNM was detected in 3 (6%) cases, demonstrating high-grade tumor budding (Bd 2/3) and invasion depth of >1,500 um. LNM was significantly correlated with tumor budding (P = 0.030). The overall median follow-up period was 41.00 ± 27.69 months and 33.16 ± 19.05 months in the ESD-alone and ESD + surgery groups, respectively (P = 0.241). Two patients in the ESD group had local recurrence and two patients died. Patients in the ESD + surgery group reported no local recurrence, distant metastasis, or disease-related death. Recurrence (P = 0.074) and survival rates (P = 0.072) were not significantly different between the two groups.</p><p><strong>Conclusions: </strong>The LNM rate was exceedingly low in patients with T1b. ESD is an effective and safe method for these patients. The necessity of additional surgical treatment after ESD should be comprehensively determined following the patient's characteristics.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2055-2060"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ability of contrast-enhanced ultrasound with Sonazoid to differentiate endometrial carcinoma from benign endometrial lesions: A preliminary, prospective, and multicenter clinical study.","authors":"Xin Li, Ying Huang, Tianan Jiang, Hong Luo, Xuejuan Dong, Tao Zhuo, Wen Cheng, Xinling Zhang, Ying Che, Bingsong Zhang, Xue Jiang, Rui Liu, Jing Zhang, Ping Liang","doi":"10.4103/jcrt.jcrt_203_24","DOIUrl":"10.4103/jcrt.jcrt_203_24","url":null,"abstract":"<p><strong>Objective: </strong>To examine the diagnostic efficacy of contrast-enhanced ultrasound (CEUS) with Sonazoid (Sonazoid-CEUS) for endometrial lesions.</p><p><strong>Methods: </strong>In this prospective and multicenter study, data were collected from 84 patients with endometrial lesions from 11 hospitals in China. All the patients received a conventional US and Sonazoid-CEUS examination. The lesion characteristics based on US and Sonazoid-CEUS imaging were collected from the case report forms. The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were determined using histopathologic diagnosis as the gold standard.</p><p><strong>Results: </strong>Of the 79 patients included, 29 were diagnosed with benign lesions and 50 with endometrial carcinoma (EC). The accuracy, sensitivity, specificity, PPV, and NPV for Sonazoid-CEUS and US at differentiating EC from benign endometrial lesions were 82.2%, 94%, 62.1%, 81.0%, and 85.7%, and 79.7%, 96%, 51.7%, 92.3%, and 88.2%, respectively, with no significant differences observed for any of the values. For Sonazoid-CEUS, the best delineators of EC versus benign lesions were early enhancement and hyperenhancement (74% vs 53.3%, P = 0.029, 68% vs 45%, P < 0.001), and lesion size enlargement (76% vs 48%, P = 0.001). Despite finding no significant difference in the enhancement patterns (P = .367), a faster wash-in pattern with the contrast agent entering before the surrounding myometrium was more common in the EC vs benign cases (92% vs 48.3%).</p><p><strong>Conclusions: </strong>Sonazoid-CEUS has higher accuracy, specificity, and comparable sensitivity for differentiating EC from benign endometrial lesions compared with conventional US. It provides complementary hemodynamics information reflective of tissue vascularization, which may improve the overall diagnostic efficiency.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2066-2073"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report.","authors":"Zhichao Li, Gang Wang, Guoliang Xue, Nan Wang, Yanting Hu, Pikun Cao, Hongchao Cai, Zhigang Wei, Xin Ye","doi":"10.4103/jcrt.jcrt_2235_24","DOIUrl":"10.4103/jcrt.jcrt_2235_24","url":null,"abstract":"<p><strong>Abstract: </strong>Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has revolutionized one of the standard most efficient treatments for EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently one of most efficient treatments in clinical practice. However, it has a potentially fatal side effect: interstitial lung disease (ILD). When severe ILD occurs, a drug substitution is often required, and there is a rising concern about which drug to choose to inhibit the progression of NSCLC and avoid aggravating while alleviating ILD. Herein, we report an NSCLC case with osimertinib-induced ILD successfully rechallenged by almonertinib. In addition, we conducted a literature review on the clinical efficacy and adverse effects of almonertinib, hoping to provide insight into NSCLC treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2148-2151"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and prognosis of testicular mixed teratoma and seminoma.","authors":"Kai Li, Fengdan Sun, Caibin Fan","doi":"10.4103/jcrt.jcrt_1109_23","DOIUrl":"10.4103/jcrt.jcrt_1109_23","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the association of demographic and clinicopathological characteristics with the survival of patients with testicular mixed teratoma and seminoma (TMTS).</p><p><strong>Methods: </strong>The data of 3296 eligible patients with TMTS who underwent surgery between 2010 and 2015 were obtained from the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and cancer-specific survival (CSS) were determined using the Kaplan-Meier survival curves. The association of demographic and clinicopathological characteristics with the OS and CSS of patients with TMTS was assessed using the Cox proportional hazard regression model.</p><p><strong>Results: </strong>The number of patients with TMTS increased annually. In Kaplan-Meier analyses, TMTS patients with advanced T stage (P < 0.001 for OS and P < 0.001 for CSS), lymph node metastasis (P < 0.001 for OS and P < 0.001 for CSS), distant metastasis (P < 0.001 for OS and P < 0.001 for CSS), no regional lymph node resection (P = 0.003 for OS and P = 0.002 for CSS), large tumor size (P = 0.001 for OS and P = 0.001 for CSS), and LVI (P < 0.001 for OS and P < 0.001 for CSS) exhibited inferior OS and CSS. Moreover, distant metastasis (HR 11.224, P < 0.001; HR 15.817, P < 0.001) and regional lymph node resection (HR 0.425, P = 0.003; HR 0.366, P = 0.004) were identified as independent prognostic factors for OS and CSS in patients with TMTS through multivariable analyses.</p><p><strong>Conclusions: </strong>Distant metastasis and lymph node metastasis were deemed important prognostic factors for OS and CSS in patients with TMTS. Therefore, a comprehensive understanding and clinical assessments of these prognostic factors are necessary before tailoring clinical management and treatment plan specified for patients with TMTS.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2074-2081"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on the structural and anti-colorectal malignant tumor properties of Shikonin.","authors":"Jinghua Chen, Jie Liu, Weiwei Nie, Xingqin Hou, Xi Zhang, Chao Liu, Linxin Si, Mingzhu Zhang, Shutao Xu, Qi Xie, Jing Liang, Yan Li","doi":"10.4103/jcrt.jcrt_933_24","DOIUrl":"10.4103/jcrt.jcrt_933_24","url":null,"abstract":"<p><strong>Abstract: </strong>Colorectal cancer is the third most prevalent malignant tumor worldwide. Despite the advancements in surgical procedures and treatment options, CRC remains a considerable cause of cancer-related mortality. Shikonin is a naphthoquinone compound that exhibits multiple biological activities, including anti-inflammatory and anti-tumor effects as well as wound healing promotion. Recently, Shikonin has been increasingly used in basic research on colorectal malignant tumors. Therefore, we explored the mechanisms of action and structural improvements of Shikonin in colorectal cancer through a literature review to provide valuable insights for the advancement of research and development of related pharmaceuticals.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"1957-1963"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triptolide exhibits dual anti-tumor effects through inhibiting autophagy and extracellular matrix activation in pancreatic cancer.","authors":"Jianxiang Gu, Zhao Shi, Siqi Zhou, Quan Zhou, Shuang Nie, Hongzhen Li, Shanshan Shen, Xiaoping Zou","doi":"10.4103/jcrt.jcrt_186_24","DOIUrl":"10.4103/jcrt.jcrt_186_24","url":null,"abstract":"<p><strong>Aim: </strong>The tumor microenvironment in pancreatic cancer, characterized by abundant desmoplastic stroma, has been implicated in the failure of chemotherapy. Therefore, developing therapeutic strategies targeting tumor and stromal cells is essential. Triptolide, a natural compound derived from the plant Tripterygium wilfordii, has shown antitumor activity in various cancers, including pancreatic cancer. However, its effects on pancreatic cancer cells and the microenvironment remain unclear. This study aimed to explore the effect of triptolide on tumor cells and the tumor microenvironment in pancreatic cancer.</p><p><strong>Methods: </strong>Cell Counting Kit-8, colony formation, apoptosis, and cell cycle assays were performed to determine the effect of triptolide on tumor cells. Additionally, co-culture assays were performed to explore the effects of the compound on cancer-associated fibroblasts (CAFs) in vitro. Orthotopic xenograft and subcutaneous tumor models were used to explore the antitumor and antistromal activation effects of triptolide in vivo. RNA sequencing was performed to identify the pathways involved in these processes in pancreatic cancer cells.</p><p><strong>Results: </strong>Triptolide inhibited the proliferation of pancreatic cancer cells and attenuated stromal activation in vitro and in vivo. Furthermore, it suppressed autophagy and induced apoptosis in pancreatic cancer cells by inhibiting the secretion of CXCL1. Extracellular matrix formation in CAFs was disrupted by suppressing the paracrine secretion of TGF-β from tumor cells.</p><p><strong>Conclusion: </strong>These findings indicate that triptolide plays a dual antitumor role against tumor cells and CAFs, thus providing new insights into treating pancreatic cancer in the future.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2041-2054"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of antegrade and retrograde laparoscopic bilateral inguinal lymphadenectomy for penile cancer.","authors":"Dingqi Sun, Hui Zhang, Tongxiang Diao, Keqin Zhang, Jinhua Wang","doi":"10.4103/jcrt.jcrt_1281_24","DOIUrl":"10.4103/jcrt.jcrt_1281_24","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate and compare the feasibility, safety, and clinical outcomes of antegrade and retrograde laparoscopic bilateral inguinal lymphadenectomy for penile cancer.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of 32 patients with penile cancer admitted between 2018 and 2022. Among them, 17 patients underwent antegrade laparoscopic inguinal lymphadenectomy (ALIL group) and 15 underwent retrograde laparoscopic inguinal lymphadenectomy (RLIL group). The key surgical procedures and techniques are described. Operative time, intraoperative blood loss, hospital stay, drainage duration, postoperative complications, and follow-up data in both groups were statistically analyzed.</p><p><strong>Results: </strong>Surgery in both groups was successfully completed without the need for intraoperative conversion to open surgery. The operative time was significantly shorter for ALIL than for RLIL (P < 0.001). Significantly less intraoperative blood loss was reported with ALIL than with RLIL (P < 0.001). The ALIL group had a significantly shorter hospital stay than the RLIL group (P = 0.027). The number of removed lymph nodes in the ALIL group differed insignificantly from that in the RLIL group (P = 0.360). Postoperative drainage duration, recurrence, short-term survival, and postoperative complications were similar between both groups.</p><p><strong>Conclusion: </strong>In the patients with penile cancer, ALIL and RLIL yielded similar perioperative outcomes. However, ALIL was associated with shorter operative time, less blood loss, and shorter hospital stays. ALIL did not require repositioning of the laparoscopic instruments, thereby simplifying the procedure and minimizing patient trauma. Additionally, if needed, pelvic lymphadenectomy could be performed simultaneously from the same trocar position used in ALIL.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2061-2065"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective.","authors":"Chenlin Wang, Ning Liang, Lili Qiao, Ya'nan Wu, Jiandong Zhang, Yan Zhang","doi":"10.4103/jcrt.jcrt_500_24","DOIUrl":"10.4103/jcrt.jcrt_500_24","url":null,"abstract":"<p><strong>Aim: </strong>Toripalimab is the first antitumor programmed cell death protein 1 (PD-1) antibody approved in China. For better patient management, it is important to understand the real-world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care.</p><p><strong>Methods: </strong>We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD-1 inhibitor (toripalimab). The Chi-square test was performed to identify clinical factors associated with the advancement of the disease. Multivariate Cox regression analysis was used to screen prognostic variables linked to real-world progression-free survival (PFS) and overall survival (OS). OS and PFS were calculated using the Kaplan-Meier method, and the comparisons were determined using the log-rank test, and continuous and categorical variables were explained using median and percentage, respectively.</p><p><strong>Result: </strong>The median OS of the estimated 80 patients was 15.85 months (95% confidence interval [CI]: 14.103-17.949 months), and the estimated PFS was 5.650 months (95% CI: 7.226-11.264 months). The longer OS and PFS correlate with the patient's staging and number of treatment lines. The PD-1 drug gave stage III patients a significantly longer PFS and OS compared to stage IV patients (PFS: 14.65 vs. 6.68, P = 0.004; OS: 21.1 vs. 13.7, P = 0.003). First- or second-line immunotherapy patients have significantly longer PFS and OS than third- or fourth-line (PFS: 6.4 vs. 3.6, P = 0.009; OS: 20.0 vs. 10.5, P = 0.003). In patients with stage IV (n = 60) with extensive metastasis, the site of metastasis is mostly 1-3 sites after receiving toripalimab. The duration of PD-1 inhibitor OS in progressive patients (n = 56) was significantly prolonged (P = 0.038).</p><p><strong>Conclusion: </strong>For patients with lung cancer, toripalimab can considerably extend PFS and OS in the first or second line and in stage III. PD-1 inhibitors are administered to patients with stage IV extensively metastatic lung cancer, which indicates an oligometastatic progression pattern, primarily in 1-3 locations, who are treated with PD-1 inhibitors. Continuing toripalimab beyond disease progression significantly prolonged OS.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2021-2028"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors retarding enhanced recovery from thermal ablation of liver tumors: A single-center prospective study.","authors":"Lanxia Zhang, Fei Dai, Qingjing Zeng, Xuqi He, Na Guo, Xiaorui Chen, Kai Li","doi":"10.4103/jcrt.jcrt_1302_24","DOIUrl":"10.4103/jcrt.jcrt_1302_24","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the risk factors that may delay enhanced recovery in the ablation of liver tumors.</p><p><strong>Methods: </strong>A total of 310 patients who underwent ultrasound-guided ablation of liver tumors under general anesthesia were prospectively enrolled. Baseline data, intraoperative parameters, and postoperative events were evaluated. Postoperative pain was scored using the visual analog scale (VAS). Logistic regression analysis was conducted for univariate and multivariate analyses.</p><p><strong>Results: </strong>The study included 42 females (13.5%) and 268 males (86.5%). The mean age of the sample was 57 ± 11 years old. The average length of stay (LOS) was 4.3 ± 2.4 days. A total of 199 out of 310 patients (64.2%) experienced moderate to severe pain (VAS score > 3). Seventy out of 310 patients (22.6%) experienced other complications. In the multivariable analysis, the number of lesions [odds ratio (95% confidence interval): 3.23 (2.15-4.84); P < 0.001], maximum diameter of lesions [1.12 (1.07-1.17), P < 0.001], and smallest distance between the lesions and the liver capsule [0.91 (0.89-0.94), P < 0.001] were risk factors for postoperative pain (VAS > 3). A history of alcohol consumption [2.62 (1.33-5.19), P = 0.005] was a risk factor for other complications. Surgical history [0.40 (0.24-0.67), P = 0.001] was a protective factor against LOS. Total operation time [1.01, 1.00-1.01, P = 0.009] was a mild risk factor for LOS.</p><p><strong>Conclusion: </strong>The number of lesions, maximum diameter of the lesions, smallest distance between the lesions and the liver capsule, total operation time, and a history of alcohol use were risk factors that may delay enhanced recovery in patients undergoing ablation of liver tumors. These findings may provide evidence to promote the use of the enhanced recovery after surgery protocol.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2103-2109"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatofibrosarcoma protuberans: A clinical and pathological observational report of Asian samples from one center.","authors":"Qili Peng, Yi Lu, Tingting Su, Pengpeng Tong, Yixiong Huang, Rui Chen","doi":"10.4103/jcrt.jcrt_2661_23","DOIUrl":"10.4103/jcrt.jcrt_2661_23","url":null,"abstract":"<p><strong>Background: </strong>Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade fibrohistiocytic tumor with malignant potential. It is considered to have a high local recurrence rate due to the characteristic invasion of the finger-like lesion into the soft tissues.</p><p><strong>Method: </strong>This retrospective study presents details of 20 DFSP patients with a history of surgery and a long follow-up period. All patients were followed up for 10 years to assess the relationship between the surgical margin and the recurrence rate. Seventeen patients provided informed consent for detailed pathological examinations.</p><p><strong>Results: </strong>Twenty Asian patients with a mean age of 42.55 years were included in this study. The location of the DFSP varied among the individuals; seven were closed by sutures, four were full-thickness skin grafts, and nine were closed using a pedicled flap. The average follow-up period was 4.185 ± 3.09 years. Recurrence was observed in 8 out of the 20 patients 1-8 years after surgery (recurrence group). A significant (P = 0.04) difference in the average surgical margin was observed between the recurrence group (1.62 ± 0.74 cm) and the remaining patients (heal group; 2.83 ± 1.43 cm). The median Ki-67 value was 12%.</p><p><strong>Conclusion: </strong>Local control of DFSP after surgery is challenging. The first choice of DFSP treatment is surgery to clear the margins and reconstruct the area. Enhancing the diagnosis rate of DFSP during the initial visit is important for the proper management and operation opportunity.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2035-2040"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}